Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Hiddo J.L. Heerspink(University Medical Center Groningen), Niels Jongs(University of Groningen), Glenn M. Chertow(Stanford University), Anna Maria Langkilde(AstraZeneca (Sweden)), John J.V. McMurray(University of Glasgow), Ricardo Correa‐Rotter(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Peter Rossing(University of Copenhagen), C. David Sjöström(AstraZeneca (Sweden)), Bergur V. Stefánsson(AstraZeneca (Sweden)), Robert D. Toto(Southwestern Medical Center), David C. Wheeler(University College London), Tom Greene(University of Utah)
Cited by 191Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis